Blanket Purchase Agreement V797D70257-VA797E17A0004

This Blanket Purchase Agreement, awarded to Grifols USA LLC on May 1, 2022, establishes a single-award indefinite delivery vehicle for the procurement of PROLASTIN-C, an alpha1-proteinase inhibitor indicated for treatment of alpha1-antitrypsin deficiency. The contract carries a ceiling value of $107.5 million with an ultimate completion date of April 30, 2027, and is funded through the National Acquisition Center, a civilian federal agency. As a firm fixed-price contract awarded without...

The National Acquisition Center established a Blanket Purchase Agreement with Adma Biologics, Inc., on August 1, 2024, against the GSA Pharmaceuticals and Drugs schedule (FSS-61-IB), for the supply of ASCENIV and BIVIGAM, with a $49 million ceiling and a period of performance through July 31, 2027. This is a single-award BPA with no set-aside category. The agreement covers pharmaceutical and plasma-derived therapeutic products for federal healthcare operations, particularly supporting the...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

This Blanket Purchase Agreement (BPA) was awarded by the Department of Health and Human Services (HHS), National Institutes of Health (NIH), to MBL International Corporation, a for-profit manufacturer of goods. The BPA covers the procurement of blood/blood products, biological materials, and chemicals. The BPA has no set-aside and was originally awarded on July 11, 2002, with an open-ended potential value. Under this BPA, three task orders have been issued to date. The first, awarded on December...

The Defense Health Agency awarded a Blanket Purchase Agreement to Nephron Sterile Compounding Center LLC on March 6, 2020, with a $4 million ceiling for pharmaceutical supplies to Brooke Army Medical Center (BAMC). Nephron Sterile Compounding Center LLC is a woman-owned small business based in West Columbia, South Carolina, operating a 503B Outsourcing Facility that specializes in sterile pharmaceutical compounding and manufacturing. The BPA carries no set-aside designation and has an ultimate...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Advanced Accelerator Applications USA Inc., a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $23.4 million single-award BPA is under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of February 3, 2025. The BPA is for the procurement of LOCAMETZ and NETSPOT, two...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc., a global pharmaceutical manufacturer, to provide the drug Oxybryta. The single-award BPA has a ceiling value of $1,300,000.00 and a period of performance through August 29, 2024. Pfizer, as a prime contractor, will supply the pharmaceutical product Oxybryta to support the agency's healthcare initiatives. Pfizer holds several significant Indefinite Delivery Vehicles with...

The National Acquisition Center established a single-award Blanket Purchase Agreement with Actelion Pharmaceuticals US, Inc. on August 22, 2024, with a ceiling of $118.5 million and ultimate completion date of August 21, 2027. The BPA is structured against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and covers seven pharmaceutical products: Tracleer, Zavesca, Ventavis, Veletri, Opsumit, Uptravi, and Opsynvi. These medications serve rare disease indications, particularly...

This Blanket Purchase Agreement (BPA), awarded on March 9, 2024, to PTC Therapeutics US, Inc. (UEI: RWWKLJ9LFHU9), under parent company PTC Therapeutics, Inc., establishes a vehicle for the procurement of Emflaza, a pharmaceutical product. The BPA represents Exercise Option Year 2 of contract number 36E79724A0007 and operates under the Pharmaceuticals and Drugs master schedule (FSS-61-IB). The National Acquisition Center, a civilian federal agency, serves as the funding entity. The agreement...

This Blanket Purchase Agreement (BPA), awarded to Ionis Pharmaceuticals, Inc. on June 16, 2025, establishes a single-award indefinite delivery vehicle with a ceiling value of $4.26 million and an ultimate completion date of September 2, 2025. The agreement is funded through the National Acquisition Center, a civilian federal agency, and does not employ any set-asides. The BPA procures TryngolZA, a specialized pharmaceutical product, with this agreement replacing a prior BPA (36E79725A0020)....